Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

Ibrutinib is a small molecule that inhibits Bruton’s tyrosine kinase (BTK), which is necessary for B cell proliferation and survival. The efficacy and durability of ibrutinib in patients with relapsed or refractory mantle cell lymphoma have been demonstrated in previous studies. The SHINE study (NCT01776840) presented by Dr. Michael L. Wang aimed to evaluate the efficacy of combining ibrutinib with the standard chemoimmunotherapy bendamustine-rituximab and rituximab maintenance in older patients with untreated patients with mantle cell lymphoma.